Novo Nordisk (NOVOB DC) exec says early oral obesity trends look incremental rather than cannibalistic and roughly 80% of Wegovy pill users are GLP-1 naive

This update from Novo Nordisk on their oral obesity treatment suggests that the market is expanding rather than just shifting existing Wegovy users.

Newsquawk StaffPublished On the live feed at 5 more headlines followed before this page went public
Newsquawk headlinesUTC

NEC Director Hassett says people who aren't in private credit should not worry about it; looking at 4% GDP growth for the year

NEC Director Hassett says they are studying a possible executive order on AI and business

Novo Nordisk (NOVOB DC) exec says early oral obesity trends look incremental rather than cannibalistic and roughly 80% of Wegovy pill users are GLP-1 naive

NEC Director Hassett says the situation with Fed Chair Powell is still uncertain; we are not threatening the independence of the Fed

Uber (UBER) CEO says demand remains incredibly strong with gross bookings +21% Y/Y, via conference call

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
  • Launch is bringing in new prescribers and new patients, and switching from competitive products appears to be more meaningful than switching from injectable Wegovy.
Context

Approximately 80% of new users are GLP-1 naive, indicating a significant influx of new patients rather than a simple swap, which could bode well for overall sales growth. Investors may see this as a positive signal for the continuing success of Novo Nordisk's product portfolio, potentially affecting their stock performance and that of competitors in the obesity treatment space.

Related headlines

The whole workspace, free to try.

Try it free